Communication

Spatial Variability in COVID-19 Mortality

Brian H. Bossak * and Catrina A. Turk

Department of Health and Human Performance, College of Charleston, Charleston, SC 29424, USA; turka@g.cofc.edu
* Correspondence: bossakbh@cofc.edu

Abstract: COVID-19 emerged as a global pandemic in the spring of 2020. Since that time, the disease has resulted in approximately 150 million cases and 3 million deaths worldwide. However, there is significant spatial variation in the rate of mortality from COVID-19. Here, we briefly explore spatial variations in COVID-19 mortality by country groupings and propose possible explanations for the differences observed. Specifically, we find that there is a statistically significant difference in COVID-19 mortality between countries grouped into categories based on (1) developed, primarily western diets and healthcare systems; (2) “Scandinavian” countries with advanced healthcare systems and generally anti-inflammatory diets, and (3) developing countries. We do not infer causality but believe that the observed associations provide hypotheses for future research investigations. Moreover, our results add further evidence to support additional exploration of vitamin D exposure/status and COVID-19 mortality.

Keywords: COVID-19; vitamin D; omega-3; spatial variability; SARS-CoV-2; diet; case-fatality rate; CFR

1. Introduction

COVID-19 (SARS-CoV-2 virus) emerged in late 2019 and rapidly became the next significant human pandemic. As of March 19th, 2021, global COVID-19 incidence was 122,489,228 cases, with 2,705,366 deaths [1]. Considerable spatial variation in the incidence of COVID-19 has been associated with a variety of factors, such as country preparedness, access to healthcare, implementation of public health interventions, and the population’s underlying health status [2–5]. In regard to individual health status, an increased risk of developing a respiratory illness is associated with chronic diseases, obesity, and vitamin deficiency [6]. COVID-19 virulence has been associated with individuals characterized as being in high-risk groups, such as the elderly, minority groups, and individuals that suffer from chronic diseases; however, many of these same individuals are susceptible to vitamin D deficiency, which may influence the severity of COVID-19 and other respiratory illnesses, particularly those with a viral origin.

Vitamins play a fundamental role in the function of the immune system and can influence immune response [6]. Vitamin D is a steroid hormone that is associated with the production of antimicrobial peptides and the expression of genes involved in the destruction of pathogens; as such, it has an important role in the induction of the innate immune response which could provide protection against influenza-like illnesses [7]. Mechanistically, it can influence the presence of receptors on the cell surface which recognize pathogenic proteins and regulate genes that are used for defenses against viruses [8]. It is also involved in protection against acute lung injury and reduces lung permeability [6]. Studies suggest that high mortality or prevalence of respiratory illnesses are associated with the cool and dry climate that occurs during the winter months [9]. However, there is reason to believe that vitamin D deficiency may serve as a confounder in the pathway between exposure to a viral pathogen and subsequent infection (and virulence of such) that could explain the seasonality and/or severity of respiratory epidemics [10].
sought to examine whether this particular vitamin can be correlated to the prevalence of COVID-19 by analysis of COVID-19 mortality in developing countries versus developed countries, with level of economic development serving as an assumed proxy for vitamin D status (e.g., less developed country = greater average outdoor exposure = less general vitamin D deficiency).

2. Materials and Methods

A total of 52 countries were selected for the analysis. Data regarding COVID-19 mortalities per 1 M population for these countries were retrieved from the Worldometers website, which contains disease data that is collated daily from official government reports [1]. The data was sorted, and countries were assigned to categories with the highest COVID-19 mortality rates per 1 M population and the countries with the lowest COVID-19 mortality rates per 1 M population. The countries found to have higher mortality rates were mostly developed countries (Developed) while the countries with the lowest mortality rate tended to be developing countries (Developing). A T-test (95% confidence) was employed to determine if there was a statistically significant difference in the mean mortality rate per 1 M population between the 20 countries with the most COVID-19 deaths per 1 M population and the 20 countries with the lowest number of deaths per 1 M.

Another factor that could be influencing the spatial heterogeneity of COVID-19 severity is lifestyle, specifically diet. Interestingly, many highly developed Scandinavian countries show a much lower severity of COVID-19 (Table 1; data from www.worldometers.info/coronavirus/ (accessed on 30 March 2021)) as represented by deaths per 1 M population (Figure 1; data from the Worldometers website). The categorization of “Scandinavian” countries as a grouping of countries here more broadly refers to medically advanced nations with potentially similar dietary exposures to anti-inflammatory foods and higher seafood/fish consumption than other country groupings, rather than solely based on geographic location in Scandinavia. Moreover, these “Scandinavian” countries possess the highest GDP per capita of the three groups (Table 2 and Figure 2; data from www.worldometers.info/gdp/gdp-per-capita (accessed on 30 March 2021)). We tested the distribution of the COVID-19 mortality rates in each country categorization for normality using the Kolmogorov-Smirnov Test for Normality. While both the Developing and “Scandinavian” country groupings were normally distributed, the mortality data for the Developed country category was non-normally distributed. As a result, we utilized the non-parametric Kruskal-Wallis (KW) test to determine if there was a statistically significant difference between COVID-19 mortality in “Scandinavian” countries compared to the 20 countries with the highest mortality rate per 1 M and the 18 countries with the lowest mortality rate per 1 M (two countries from the initial analysis of the 20 countries with the lowest COVID-19 mortality per 1 M population were re-classified into the “Scandinavian” group for further analysis: New Zealand and Singapore).
Figure 1. Scatter plot of the average COVID-19 death rate per 1 M population versus average GDP of each group of countries, as of 30 March 2021. A KW test on COVID-19 mortality per 1 M population showed a statistically significant difference for these three groupings of countries ($p < 0.01$).

Table 1. The COVID-19 mortality rate per 1 M population for the 20 countries with the highest and lowest rates, and “Scandinavian” countries (Singapore and New Zealand moved to “Scandinavian” here).

| Developed Countries | Rate of Death per 1 M Pop | Developing Countries | Rate of Death per 1 M Pop | “Scandinavian” Countries | Rate of Death per 1 M Pop |
|---------------------|---------------------------|----------------------|---------------------------|--------------------------|---------------------------|
| Gibraltar           | 2672                      | Burundi              | 0.2                       | Japan                    | 61                        |
| San Marino          | 2119                      | Tanzania             | 0.3                       | Denmark                  | 405                       |
| Belgium             | 1883                      | Vietnam              | 0.4                       | South Korea              | 31                        |
| Slovenia            | 1816                      | Taiwan               | 0.4                       | Iceland                  | 85                        |
| Czechia             | 1792                      | Mongolia             | 0.6                       | Norway                   | 114                       |
Table 1. Cont.

| Developed Countries | Rate of Death per 1 M Pop | Developing Countries | Rate of Death per 1 M Pop | “Scandinavian” Countries | Rate of Death per 1 M Pop |
|---------------------|--------------------------|----------------------|--------------------------|--------------------------|--------------------------|
| UK                  | 1770                     | Thailand             | 1                        | Estonia                  | 143                      |
| Italy               | 1585                     | Papua New Guinea     | 1                        | Finland                  | 134                      |
| Portugal            | 1568                     | Bhutan               | 1                        | Uruguay                  | 171                      |
| USA                 | 1535                     | Eritrea              | 2                        | Cuba                     | 28                       |
| Bosnia and Herzegovina | 1524               | Fiji                 | 2                        | Cyprus                   | 190                      |
| Montenegro          | 1512                     | Western Sahara       | 2                        | Australia                | 35                       |
| Hungary             | 1483                     | China                | 3                        | Jamaica                  | 139                      |
| North Macedonia     | 1470                     | Benin                | 6                        | Singapore                | 5                        |
| Spain               | 1435                     | Uganda               | 7                        | New Zealand              | 5                        |
| Bulgaria            | 1423                     | Ivory Coast          | 7                        |                         |                          |
| Liechtenstein       | 1414                     | Guinea               | 7                        |                         |                          |
| Mexico              | 1385                     | Burkhina Faso        | 7                        |                         |                          |
| Andorra             | 1383                     | Niger                | 7                        |                         |                          |
| Peru                | 1349                     |                      |                          |                         |                          |
| Croatia             | 1328                     |                      |                          |                         |                          |
| Average             | 1622                     |                      |                          |                          | 149                      |

Table 2. The GDP per capita for the countries with the highest and lowest death rates per 1 M population and “Scandinavian” countries.

| Developed Countries | GDP per Capita | Developing Countries | GDP per Capita | “Scandinavian” Countries | GDP per Capita |
|---------------------|----------------|----------------------|----------------|--------------------------|----------------|
| Gibraltar           | N/A            | Burundi              | 293           | Japan                    | 38,214         |
| San Marino          | 48,495         | Tanzania             | 975           | Denmark                  | 57,545         |
| Belgium             | 43,325         | Vietnam              | 2366          | South Korea              | 24,490         |
| Slovenia            | N/A            | Taiwan               | N/A           | Iceland                  | 29,958         |
| Czechia             | 20,291         | Mongolia             | 3672          | Norway                   | 75,428         |
| UK                  | 39,532         | Thailand             | 6579          | Estonia                  | 20,170         |
| Italy               | 32,038         | Papua New Guinea     | 2434          | Finland                  | 45,778         |
| Portugal            | 21,316         | Bhutan               | 3391          | Uruguay                  | 16,341         |
| USA                 | 59,939         | Eritrea              | N/A           | Cuba                     | 8541           |
| Bosnia and Herzegovina | 5387             | Fiji                 | 5768          | Cyprus                   | 18,695         |
| Montenegro          | 7720           | Western Sahara       | N/A           | Australia                | 54,831         |
| Hungary             | 14,364         | China                | 8612          | Jamaica                  | 5061           |
| North Macedonia     | 5418           | Benin                | 827           | Singapore                | 56,746         |
| Spain               | 28,175         | Uganda               | 631           | New Zealand              | 43,415         |
| Bulgaria            | 8197           | Ivory Coast          | 1529          |                         |                |
| Liechtenstein       | N/A            | Guinea               | 868           |                         |                |
| Mexico              | 9224           | Burkina Faso         | 642           |                         |                |
| Andorra             | 39,128         | Niger                | 376           |                         |                |
| Peru                | 6723           |                      |               |                          |                |
| Croatia             | 13,200         |                      |               |                          |                |
| Average             | 23,675         |                      | 2756          |                          | 35,372         |

3. Results

Countries that were found to have the highest death rates per 1 M population and the countries that were found to have the lowest death rates per 1 M population for COVID-19 were tested for statistical significance. A T-test demonstrated that there is a statistically significant difference between COVID-19 mortality in developed countries and COVID-19 mortality in developing countries + two of the “Scandinavian” countries as described above (p < 0.001). Moreover, this significant difference was found to be directional; there is a much higher rate of COVID-19 mortality per 1 M population in developed countries versus developing countries. The results of the Kruskal-Wallis (KW) test indicated a statistically significant difference between the mortality rates of the three
groupings of countries ($H = 11.7815, p$-value $= 0.00276$). Thus, the results suggest that there is spatial variability in the reported COVID-19 severity between developing, developed, and Scandinavian-type countries as defined here.

There are many possible explanations for the observed statistical difference in mortality rates. This vast difference in severity could be associated with other mechanisms such as better healthcare or higher rates of testing. However, there is one factor that is different between “Scandinavian” countries and other western countries that are exhibiting drastically higher mortality from COVID-19. Many “Scandinavian” countries tend to incorporate an abundance of seafood into their diets which could account for some of the difference in COVID-19 severity. Seafood contains vitamin D; therefore, this surplus of vitamin D incorporated into their diet could demonstrate the difference of severity between developed countries. Moreover, many types of seafood are high in levels of omega-3 fatty acids, which contain anti-inflammatory properties. The developed countries that have a high death rate for COVID-19 per 1 M population tend to have more saturated fats, sugar, and red meat in their diets. Therefore, there could be multiple factors related to diet, lifestyle, and vitamin D synthesis that could be associated with the severity of COVID-19 infection distinguished by national identities, perhaps partly explaining why there is such a drastic difference in COVID-19 mortality rates between developed countries, developing countries, and “Scandinavian” countries.

4. Discussion

Our analysis demonstrates that there is a statistically significant difference in COVID-19 severity between countries (and country groupings) and across space. One possible explanation is that the significant difference in COVID-19 severity may be associated with vitamin D exposure or lack thereof, therefore correlating with vitamin D deficiency. Vitamin D status is largely associated with exposure to sunlight which is significantly reduced in the winter months and could contribute to the increased prevalence in respiratory illnesses during this time [8]. In most developing countries, lifestyle tends to be targeted towards outdoor activities which could reduce prevalence of vitamin D deficiency. In developed countries, sun exposure may generally be more limited because a greater portion of the lifespan is being spent indoors (office workers, institutionalized populations, retail, and others). This could be one factor associated with the increasing prevalence of vitamin D deficiency in developed countries which would have a corresponding effect on immune response: therefore, possibly increasing severe cases of respiratory illnesses for a given population size. For example, this association has been demonstrated in the elderly population, which also tends to be one of the most susceptible populations to COVID-19. Many elderly individuals have vitamin D deficiency due to reduced amount of vitamin D in their diet, decreased skin synthesis of vitamin D, and limited time outdoors [11].

However, these differences are more evident when COVID-19 severity is stratified by economic development factors (Figure 1) rather than simply location and become more pronounced when lifestyle and dietary considerations are explored. While we cannot infer a causal association between lifestyle factors, such as time spent outdoors or exposure to sunlight, these are distinctive parameters within and between each grouping of countries and have been introduced in association with health and disease in prior studies [12,13]. Moreover, different countries responded to the pandemic in a spectrum of actions, which may partially explain the observed spatial variation in mortality rates; for example, Italy was one of the countries with a significant outbreak of COVID-19 early in the pandemic, albeit in a region of the country (Po Valley) distinct from the rest of the state [14]. Within and between countries, ambient environmental conditions may also have influenced aggregate COVID-19 mortality, such as genetics, climate, and humidity [15].

In terms of potential weaknesses or limitations to our approach, we recognize that country-level reporting of cases and deaths from COVID-19 could influence these results. For example, underreporting or delayed reporting of cases or deaths in countries indicating low COVID-19 morbidity/mortality could bias any correlative statistical associations. It is
possible that associations between GDP per capita and COVID-19 mortality may also be spurious or random. However, many of the countries that have reporting low COVID-19 mortality per 1 M population to this point in the pandemic ("Scandinavian") have advanced healthcare systems with no strong reason to underreport. Moreover, we utilize mortality data which may be somewhat less likely to suffer from underreporting bias than COVID-19 incidence data.

5. Conclusions
There was a significant correlation between the number of COVID-19 deaths per 1 M population and the level of development within and between countries. Surprisingly, the rate of mortality per 1 M population was higher in western developed countries with respect to developing nations and/or countries with the highest development of healthcare provision (termed “Scandinavian”). There may be numerous factors that could explain these observed differences, including some that may be associated with the lifestyle and societal norms in specific countries (e.g., diet and nutrition, physical activity, genetics, environment, sunlight exposure, or other factors). The factors considered here need further exploration; however, if additional evidence that vitamin D deficiency be a factor in the variance of COVID-19 mortality is observed, this could suggest vitamin D supplementation as a possible public health intervention in the future. The interaction(s) between vitamin D and its role in general immune status (as well as specific associations with COVID-19 severity) merit further studies. Early research results on these purported associations support further exploration of this potential factor on disease outcomes and virulence [16–19]. Moreover, associations between COVID-19 mortality and diet/lifestyle factors, such as nutritional status or consumption of seafood, warrant further exploration.

Author Contributions: Conceptualization, B.H.B.; methodology, C.A.T.; validation, B.H.B. and C.A.T.; formal analysis, B.H.B. and C.A.T.; data curation, C.A.T.; writing—original draft preparation, C.A.T.; writing—review and editing, B.H.B. and C.A.T.; visualization, B.H.B. and C.A.T.; supervision, B.H.B.; project administration, B.H.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: https://www.worldometers.info/coronavirus/ (accessed on 30 March 2021) and www.worldometers.info/gdp/gdp-per-capita (accessed on 30 March 2021).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Worldometer, COVID-19 Coronavirus Pandemic 2020. Available online: https://www.worldometers.info/coronavirus/ (accessed on 30 March 2021).
2. Hopman, J.; Mehtar, S. Country level analysis of COVID-19 policies. Eclinicalmedicine 2020, 25, 1–2. [CrossRef] [PubMed]
3. Chen, J.; Guo, X.; Pan Haozhi, P.; Zhong, S. What determines a city’s resilience against epidemic outbreak: Evidence from China’s COVID-19 experience. Sustain. Cities Soc. 2021, 70, 102892. [CrossRef] [PubMed]
4. Gilbert, M.; Colizza, V. Preparedness and Vulnerability of African countries against importations of COVID-19: A modelling study. Lancet 2020, 395, 871–877. [CrossRef]
5. Lakhani, A. Introducing the Percent, Number, Availability, and Capacity [PNAC] Spatial Approach to Identify Priority Rural Areas Requiring Targeted Health Support in Light of COVID-19: A modelling study. J. Rural Health 2020, 37, 149–152. [CrossRef] [PubMed]
6. Fedele, D.; Francesco, A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic. Nutrition 2021, 81, 111016. [CrossRef] [PubMed]
7. Hernández, J.L.; Nan, D.; Fernandez-Ayala, M.; García-Unaueta, M.; Hernández-Hernández, M.A. Vitamin D status in hospitalized patients with SARS-CoV-2 Infection. Endocr. Soc. 2020, 106, e1343–e1353. [CrossRef]
8. Mohan, M.; Cherian, J.; Sharma, A. Exploring links between vitamin D deficiency and COVID-19. PLoS Pathog. 2020, 16, e1008874. [CrossRef] [PubMed]
9. Tamerius, J.; Nelson, M.I.; Zhou, S.Z.; Viboud, C.; Miller, M.A.; Alonso, W.J. Global Influenza Seasonality: Reconciling Patterns across Temperate and Tropical Regions. *Environ. Health Perspect.* 2011, 119, 439–445. [CrossRef] [PubMed]

10. Nurshad, A. Role of Vitamin D in preventing of COVID-19 infection, progression and severity. *J. Infect. Public Health* 2020, 13, 1373–1380.

11. Lang, P.O.; Samaras, D. Aging Adults and Seasonal Influenza: Does the vitamin D status (H)arm the Body? *J. Aging Res.* 2012, 2012, 1–8. [CrossRef] [PubMed]

12. Pierre, J. Can Urban Regimes Travel in Time and Space? Urban Regime Theory, Urban Governance theory, and Comparative Urban Politics. *Urban Aff. Rev.* 2014, 50, 864–889. [CrossRef]

13. Zhang, L.; Cong, C.; Pan, H.; Cai, Z.; Cvetkovic, V.; Deal, B. Socioecological informed comparative modeling to promote sustainable urban policy transitions: Case Study in Chicago and Stockholm. *J. Clean. Prod.* 2021, 281, 125050. [CrossRef]

14. Nioli, M.; Napoli, P.; Lobina, J.; Fossarello, M.; d’Aloja, E. COVID-19 and Italian Healthcare Workers From the initial Sacrifice to the mRNA Vaccine: Pandemic Chrono-History, Epidemiological Data, Ethical Dilemmas, and Future Challenges. *Front. Public Health* 2021, 8, 591900.

15. Napoli, P.; Nioli, M. Global Spread of Coronavirus Disease 2019 and Malaria: An Epidemiological Paradox in the Early Stage of A Pandemic. *J. Clin. Med.* 2020, 9, 1138. [CrossRef] [PubMed]

16. Turrubuates-Hernandez, F.; Sanchez-Zuno, G.; Gonzalez-Estevez, G.; Hernandez-Bello, J.; Macedo-Ojeda, G.; Munoz-Valle, J. Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America. *Int. J. Mol. Med.* 2021, 47, 1107–3756.

17. Gasmi, A.; Tippairote, T.; Mukawdiya, P.; Peana, M.; Menzel, A.; Dadar, M.; Benahmed, A.; Bjorklund, G. Micronutrients as immunomodulatory tools for COVID-19 management. *Clin. Immunol.* 2020, 220, 108545. [CrossRef] [PubMed]

18. Pinheiro, M.; Fabbri, A.; Infante, M. Cytokine storm modulation in COVID-19: A proposed role for Vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i). *Immunotherapy* 2021, 13, 753–765. [CrossRef] [PubMed]

19. Ünsal, Y.A.; Gül, Ö.O.; Cander, S.; Ersoy, C.; Aydemir, E.; Ateş, C.; Uzun, Z.; Armağan, E.; Ünsal, O.; Ertürk, E. Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection. *J. Endocrinol. Investig.* 2021, 1–7. [CrossRef]